In vitro, GM-CSF–expressing B cells efficiently activated myeloid cells in a GM-CSF–dependent manner, and in vivo, B cell depletion therapy resulted in a GM-CSF–dependent decrease in pro-inflammatory myeloid responses of MS patients. This evidence concerns the gene CSF2 and myeloid sarcoma.